127 related articles for article (PubMed ID: 1902868)
21. Levels of three hemostatic factors in relation to serum lipids. Monocyte procoagulant activity, tissue plasminogen activator, and type-1 plasminogen activator inhibitor.
Crutchley DJ; McPhee GV; Terris MF; Canossa-Terris MA
Arteriosclerosis; 1989; 9(6):934-9. PubMed ID: 2511826
[TBL] [Abstract][Full Text] [Related]
22. Hypertension and hemostatic/fibrinolytic balance disorders.
Tabak O; Gelisgen R; Uzun H; Kalender B; Balci H; Curgunlu A; Simsek G; Karter Y
Clin Invest Med; 2009 Dec; 32(6):E285. PubMed ID: 20003834
[TBL] [Abstract][Full Text] [Related]
23. [Relationship of lipoprotein(a) to fibrinolytic activities in healthy subjects].
Xiong X; Zhao S; Wang Z; Lo L; Huang Q
Hunan Yi Ke Da Xue Xue Bao; 1998; 23(6):555-7. PubMed ID: 10806767
[TBL] [Abstract][Full Text] [Related]
24. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
[TBL] [Abstract][Full Text] [Related]
25. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
Wiman B; Andersson T; Hallqvist J; Reuterwall C; Ahlbom A; deFaire U
Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):2019-23. PubMed ID: 10938026
[TBL] [Abstract][Full Text] [Related]
26. Decreased fibrinolytic response to adrenergic stimulation in hypertensive patients.
Palermo A; Bertalero P; Pizza N; Amelotti R; Libretti A
J Hypertens Suppl; 1989 Dec; 7(6):S162-3. PubMed ID: 2517301
[TBL] [Abstract][Full Text] [Related]
27. Fluctuation of tPA and PAI-1 antigen levels in plasma: difference of their fluctuation patterns between male and female.
Urano T; Sumiyoshi K; Nakamura M; Mori T; Takada Y; Takada A
Thromb Res; 1990 Oct; 60(2):133-9. PubMed ID: 2126399
[TBL] [Abstract][Full Text] [Related]
28. Disturbances in the tissue plasminogen activator/plasminogen activator inhibitor (TPA/PAI) system in systemic lupus erythematosus.
Ruiz-Argüelles GJ; Ruiz-Argüelles A; Lobato-Mendizábal E; Díaz-Gomez F; Pacheco-Pantoja E; Drenkard C; Alarcón-Segovia D
Am J Hematol; 1991 May; 37(1):9-13. PubMed ID: 1902623
[TBL] [Abstract][Full Text] [Related]
29. [Relationship of age, sex, body weight, smoking, blood lipids and fibrinolytic activities in healthy subjects].
Xiong X; Wang Z; Zhao S
Hunan Yi Ke Da Xue Xue Bao; 1999; 24(1):65-7. PubMed ID: 11938745
[TBL] [Abstract][Full Text] [Related]
30. Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure. The Northern Sweden MONICA Study.
Eliasson M; Evrin PE; Lundblad D
J Clin Epidemiol; 1994 May; 47(5):513-24. PubMed ID: 7730877
[TBL] [Abstract][Full Text] [Related]
31. [Tissue plasminogen activator, its inhibitor and other factors of the blood fibrinolytic system in stable coronary heart disease].
Zateĭshchikov DA; Averkov OV; Gratsianskiĭ NA; Dobrovol'skiĭ AB; Storozhilova AN
Kardiologiia; 1992 Feb; 32(2):9-12. PubMed ID: 1527946
[TBL] [Abstract][Full Text] [Related]
32. Normal plasminogen activator inhibitor levels at long-term follow-up after jejuno-ileal bypass surgery in morbidly obese individuals.
Sylvan A; Rutegård JN; Janunger KG; Sjölund B; Nilsson TK
Metabolism; 1992 Dec; 41(12):1370-2. PubMed ID: 1461144
[TBL] [Abstract][Full Text] [Related]
33. Relationships of blood pressure to fibrinolysis: influence of anthropometry, metabolic profile and behavioural variables.
Cigolini M; Targher G; Seidell JC; Tonoli M; Schiavon R; Agostino G; De Sandre G
J Hypertens; 1995 Jun; 13(6):659-66. PubMed ID: 7594424
[TBL] [Abstract][Full Text] [Related]
34. Beneficial effect of a moderately energy-restricted diet on fibrinolytic factors in non-obese men.
Velthuis-te Wierik EJ; Meijer P; Kluft C; van den Berg H
Metabolism; 1995 Dec; 44(12):1548-52. PubMed ID: 8786722
[TBL] [Abstract][Full Text] [Related]
35. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor.
Ridker PM; Vaughan DE; Stampfer MJ; Manson JE; Shen C; Newcomer LM; Goldhaber SZ; Hennekens CH
Circulation; 1992 May; 85(5):1822-7. PubMed ID: 1572039
[TBL] [Abstract][Full Text] [Related]
36. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke.
Johansson L; Jansson JH; Boman K; Nilsson TK; Stegmayr B; Hallmans G
Stroke; 2000 Jan; 31(1):26-32. PubMed ID: 10625711
[TBL] [Abstract][Full Text] [Related]
37. Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels.
Bröijersen A; Eriksson M; Wiman B; Angelin B; Hjemdahl P
Arterioscler Thromb Vasc Biol; 1996 Apr; 16(4):511-6. PubMed ID: 8624772
[TBL] [Abstract][Full Text] [Related]
38. Fibrinolytic response to venous occlusion in healthy subjects: relationship to age, gender, body weight, blood lipids and insulin.
Stegnar M; Pentek M
Thromb Res; 1993 Jan; 69(1):81-92. PubMed ID: 8465277
[TBL] [Abstract][Full Text] [Related]
39. Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia.
Sebestjen M; Zegura B; Guzic-Salobir B; Keber I
Wien Klin Wochenschr; 2001 Feb; 113(3-4):113-8. PubMed ID: 11253736
[TBL] [Abstract][Full Text] [Related]
40. Beta blockers, Lp(a), hypertension, and reduced basal fibrinolytic activity.
Glueck CJ; Glueck HI; Hamer T; Speirs J; Tracy T; Stroop D
Am J Med Sci; 1994 May; 307(5):317-24. PubMed ID: 7909648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
